Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Decision to take tamoxifen is difficult for many women at high risk of cancer
January 6th, 2005
Many women at high risk for breast cancer are foregoing tamoxifen, the first U.S. Food and Drug Administration-approved drug for prevention of breast cancer, due to concerns about side effects, increased risk of other cancers, and lack of information, a new study shows. "While the availability of tamoxifen is a significant advance in breast cancer prevention, it also presents a complicated decision for women at high risk for the disease," said Sharon Bober, PhD, clinical instructor in the Department of Psychiatry at Harvard Medical School, staff psychologist at the Beth Israel Deaconess Medical Center and Dana-Farber Cancer Institute, and lead author of the study, which...
Source: Women's Health Weekly (2005-01-06)
|
